Skip to main content Back to Top
Advertisement

5/26/2022

Iohexol Injection

Products Affected - Description

    • Omnipaque solution for injection, GE Healthcare, 140 mg/mL, 50 mL +PLUSPAK bottle, 10 count, NDC 00407-1401-52
    • Omnipaque solution for injection, GE Healthcare, 180 mg/mL, 10 mL glass vial, 10 count, NDC 00407-1411-10
    • Omnipaque solution for injection, GE Healthcare, 180 mg/mL, 20 mL glass vial, 10 count, NDC 00407-1411-20
    • Omnipaque solution for injection, GE Healthcare, 240 mg/mL, 10 mL glass vial, 10 count, NDC 00407-1412-10
    • Omnipaque solution for injection, GE Healthcare, 240 mg/mL, 100 mL +PLUSPAK bottle, 10 count, NDC 00407-1412-33
    • Omnipaque solution for injection, GE Healthcare, 240 mg/mL, 150 mL fill in 200 mL +PLUSPAK bottle, 10 count, NDC 00407-1412-34
    • Omnipaque solution for injection, GE Healthcare, 240 mg/mL, 20 mL glass vial, 10 count, NDC 00407-1412-20
    • Omnipaque solution for injection, GE Healthcare, 240 mg/mL, 200 mL +PLUSPAK bottle, 10 count, NDC 00407-1412-35
    • Omnipaque solution for injection, GE Healthcare, 240 mg/mL, 50 mL +PLUSPAK bottle, 10 count, NDC 00407-1412-30
    • Omnipaque solution for injection, GE Healthcare, 240 mg/mL, 50 mL +PLUSPAK bottle, 10 count, NDC 00407-1412-38
    • Omnipaque solution for injection, GE Healthcare, 300 mg/mL, 10 mL glass vial, 10 count, NDC 00407-1413-10
    • Omnipaque solution for injection, GE Healthcare, 300 mg/mL, 100 mL +PLUSPAK bottle, 10 count, NDC 00407-1413-87
    • Omnipaque solution for injection, GE Healthcare, 300 mg/mL, 100 mL +PLUSPAK bottle, 10 count, NDC 00407-1413-63
    • Omnipaque solution for injection, GE Healthcare, 300 mg/mL, 125 mL fill in 150 mL glass bottle, 10 count, NDC 00407-1413-53
    • Omnipaque solution for injection, GE Healthcare, 300 mg/mL, 150 mL +PLUSPAK bottle, 10 count, NDC 00407-1413-88
    • Omnipaque solution for injection, GE Healthcare, 300 mg/mL, 150 mL fill in 200 mL +PLUSPAK bottle, 10 count, NDC 00407-1413-65
    • Omnipaque solution for injection, GE Healthcare, 300 mg/mL, 200 mL +PLUSPAK bottle, 10 count, NDC 00407-1413-66
    • Omnipaque solution for injection, GE Healthcare, 300 mg/mL, 30 mL fill in 50 mL +PLUSPAK bottle, 10 count, NDC 00407-1413-59
    • Omnipaque solution for injection, GE Healthcare, 300 mg/mL, 50 mL +PLUSPAK bottle, 10 count, NDC 00407-1413-61
    • Omnipaque solution for injection, GE Healthcare, 300 mg/mL, 50 mL +PLUSPAK bottle, 10 count, NDC 00407-1413-86
    • Omnipaque solution for injection, GE Healthcare, 300 mg/mL, 500 mL +PLUSPAK bottle, 10 count, NDC 00407-1413-89
    • Omnipaque solution for injection, GE Healthcare, 300 mg/mL, 500 mL +PLUSPAK bottle, 10 count, NDC 00407-1413-68
    • Omnipaque solution for injection, GE Healthcare, 300 mg/mL, 500 mL +PLUSPAK bottle, 10 count, NDC 00407-1413-72
    • Omnipaque solution for injection, GE Healthcare, 300 mg/mL, 75 mL fill in 100 mL +PLUSPAK bottle, 10 count, NDC 00407-1413-62
    • Omnipaque solution for injection, GE Healthcare, 350 mg/mL, 100 mL +PLUSPAK bottle, 10 count, NDC 00407-1414-84
    • Omnipaque solution for injection, GE Healthcare, 350 mg/mL, 100 mL +PLUSPAK bottle, 10 count, NDC 00407-1414-91
    • Omnipaque solution for injection, GE Healthcare, 350 mg/mL, 125 mL fill in 150 mL glass bottle, 10 count, NDC 00407-1414-76
    • Omnipaque solution for injection, GE Healthcare, 350 mg/mL, 125 mL fill in 200 mL bottle with hanger bottle, 10 count, NDC 00407-1414-85
    • Omnipaque solution for injection, GE Healthcare, 350 mg/mL, 125 mL fill in 200 mL +PLUSPAK bottle, 10 count, NDC 00407-1414-95
    • Omnipaque solution for injection, GE Healthcare, 350 mg/mL, 150 mL +PLUSPAK bottle, 10 count, NDC 00407-1414-86
    • Omnipaque solution for injection, GE Healthcare, 350 mg/mL, 150 mL fill in 200 mL +PLUSPAK bottle, 10 count, NDC 00407-1414-93
    • Omnipaque solution for injection, GE Healthcare, 350 mg/mL, 200 mL +PLUSPAK bottle, 10 count, NDC 00407-1414-87
    • Omnipaque solution for injection, GE Healthcare, 350 mg/mL, 200 mL +PLUSPAK bottle, 10 count, NDC 00407-1414-94
    • Omnipaque solution for injection, GE Healthcare, 350 mg/mL, 50 mL +PLUSPAK bottle, 10 count, NDC 00407-1414-82
    • Omnipaque solution for injection, GE Healthcare, 350 mg/mL, 50 mL +PLUSPAK bottle, 10 count, NDC 00407-1414-89
    • Omnipaque solution for injection, GE Healthcare, 350 mg/mL, 500 mL +PLUSPAK bottle, 10 count, NDC 00407-1414-72
    • Omnipaque solution for injection, GE Healthcare, 350 mg/mL, 500 mL +PLUSPAK bottle, 10 count, NDC 00407-1414-88
    • Omnipaque solution for injection, GE Healthcare, 350 mg/mL, 500 mL +PLUSPAK bottle, 10 count, NDC 00407-1414-98
    • Omnipaque solution for injection, GE Healthcare, 350 mg/mL, 75 mL fill in 100 mL +PLUSPAK bottle, 10 count, NDC 00407-1414-90

Reason for the Shortage

    • The GE Healthcare production facility for iodinated contrast media located in Shanghai, China was shut down temporarily due to a COVID-19 lockdown. The facility is open again and production is being resumed as allowed by local regulations. The company estimates a recovery date of July 2022. https://www.ge.com/news/press-releases/ge-healthcare-update-on-iodinated-contrast-media

Available Products

    • There is insufficient supply for usual ordering

Estimated Resupply Dates

    • GE Healthcare has all Omnipaque presentations on back order and the company is allocating product as it becomes available.

Alternative Agents & Management

    • More information can be found at Considerations for Imaging Contrast Shortage Management and Conservation
    • Non-ionic, low osmolality contrast media in current use include iopamidol, iohexol, iopromide, and ioversol.
    • Iodixanol (iso-osmolality agent) is also included in the low osmolality contrast media category.[1]
    • Table 1 lists specifications of iodinated intravascular contrast media products.
    • The American College of Radiology (ACR) has issued a statement addressing the shortage of iodinated contrast media. https://www.acr.org/Advocacy-and-Economics/ACR-Position-Statements/Contrast-Media-Shortage
    Table 1. Table 1 Specifications of Iodinated Intravascular Contrast Media1
    Product Generic name (concentration)IonicityIodine (mg/mL)Viscosity at 20 - 25 degrees C (cps)Viscosity at 37 degrees C (cps)Osmolality (mOsm/kg of water)
    Omnipaque 140 Iohexol (302)Nonionic1402.31.5322
    Ultravist 150iopromideNonionic1502.31.5328
    Omnipaque 180iohexol (388)Nonionic1803.12408
    Isovue 200iopamidol (408)Nonionic2003.32.0413
    Omnipaque 240iohexol (518)Nonionic2405.83.4520
    Ultravist 240iopromideNonionic2404.92.8483
    Isovue 250iopamido (510)Nonionic2505.43.0524
    Visipaque 270iodixanol (550)Nonionic27012.76.3290
    Conrayiothalamate (600)Ionic282641400
    Isovue 300iopamidol (612)Nonionic3008.84.7616
    Omnipaque 300iohexol (647)Nonionic30011.86.3672
    Optiray 300ioversol (640)Nonionic3008.25.5651
    Ultravist 300iopromideNonionic3009.24.9607
    Optiray 320ioversol (680)Nonionic3209.95.8702
    Visipaque 320iodixanol (652)Nonionic32026.611.8290
    Optiray 350ioversol (740)Nonionic35014.39.0792
    Omnipaque 350iohexol (755)Nonionic35020.410.4844
    Isovue 370iopamidol (755)Nonionic37020.99.4796
    Ultravist 370IopromideNonionic37022.010.0774

References

    1. ACR Manual on Contrast Media. American College of Radiology. https://www.acr.org/-/media/ACR/Files/Clinical-Resources/Contrast_Media.pdf. 2021.

Updated

Updated May 26, 2022 by Michelle Wheeler, PharmD, Drug Information Specialist. Created April 29, 2022 by Leslie Jensen, PharmD, Drug Information Specialist. © 2022, Drug Information Service, University of Utah, Salt Lake City, UT.

ADVERTISEMENT

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.